An open label, single treatment, single period, single oral dose pharmacokinetic study of remogliflozin etabonate tablet 250 mg of Glenmark Pharmaceuticals Ltd., India in normal, healthy, adult, human male subjects under fasting condition.

Trial Profile

An open label, single treatment, single period, single oral dose pharmacokinetic study of remogliflozin etabonate tablet 250 mg of Glenmark Pharmaceuticals Ltd., India in normal, healthy, adult, human male subjects under fasting condition.

Completed
Phase of Trial: Phase I

Latest Information Update: 16 Jan 2018

At a glance

  • Drugs Remogliflozin etabonate (Primary)
  • Indications Non-alcoholic steatohepatitis; Type 2 diabetes mellitus
  • Focus Pharmacokinetics
  • Sponsors Glenmark Pharmaceuticals Ltd
  • Most Recent Events

    • 08 Jan 2018 Status changed from not yet recruiting to completed.
    • 12 Dec 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top